Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06069583
Other study ID # MP-02-2024-11714
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 5, 2024
Est. completion date January 5, 2028

Study information

Verified date September 2023
Source McGill University
Contact Anne-Sophie Brazeau, PhD
Phone 5143987848
Email anne-sophie.brazeau@mcgill.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will conduct a trial to evaluate if an online training and support platform can help adults living with type 1 diabetes (T1D) in their diabetes self-management. Investigators will compare a group that has access to the "Support" platform through their usual medical care to a group that accesses the platform independently. The first group will be recruited through four participating clinics in the province of Quebec (Canada). The second group will be composed of adults living with T1D across Canada. Participants will have access to the platform for 12 months and will be asked to complete online questionnaires at the beginning and after 6 and 12 months, and share their glucose reader data with the research team. A subgroup of participants as well as healthcare professionals from the four clinics will be invited to participate in an individual interview aiming to understand the barriers and facilitators of integration "Support" in clinical care.


Description:

Type 1 diabetes (T1D) is a chronic condition which requires life-sustaining insulin therapy as well as knowledge, skills and confidence to self-manage. Tailored diabetes self-management education (DSME) should be offered to all people living with diabetes (PWT1D) at diagnosis, but also in a timely manner according to needs. DSME has the potential to improve quality of life and decrease diabetes complications. Despite the positive outcomes of other DSME programs, participation rates of DSME vary greatly perhaps because access remains sub-optimal. Also, healthcare professionals (HCPs) face a challenge to remain aware of the particularities of T1D and stay up-to-date on the rapidly evolving evidence-based knowledge, technologies and therapies available. The investigators propose to examine an online training and peer support platform, called "Support" as a potential alternative for DSME. The overall purpose of this hybrid effectiveness-implementation study is to investigate if integrating the "Support" platform to routine medical care of adults living with T1D (i.e., diabetes team referring to the "Support" platform during appointments) can improve diabetes self- management, in comparison with navigating the "Support" platform independently of usual care (i.e., the platform not being discussed during appointment) (Effectiveness), and to study the factors affecting its implementation in real-life settings (Implementation). This study is a mixed-method multi-site, 2 arms, non-randomized, type 1 hybrid effectiveness-implementation trial. ARM 1: PWT1D participants will have access to Support as part of their regular care (their HCPs will use "Support" in their care). PWT1D participants in ARM 1 are followed in one of the 4 participating clinics either in-person or remotely or hybrid. ARM 2: PWT1D participants will have access to "Support", independently from their regular care (they may initiate discussion about the platform with their diabetes care team who might register themselves on the platform, but will not prompt to any specific section on the platform and will not receive any training about the platform). PWT1D participants in ARM 2 can be followed in any other clinics in Canada. Implementation data will be gathered through HCP participants in the participating clinics. Participants will have to answer online surveys at baseline, 6 months and 12 months. After completing the baseline questionnaire, they will receive an access to the platform. A subgroup of participants as well as participating HCPs will be invited for individual interviews to discuss their experience in using the platform.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 322
Est. completion date January 5, 2028
Est. primary completion date January 5, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of T1D (including LADA - latent autoimmune diabetes in adults) - Have access to Internet - Use of an active email address - Comprehension of English or French - Live in Canada Exclusion Criteria: - Unable to use the Support platform

Study Design


Intervention

Behavioral:
Support platform
The study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar. Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D.

Locations

Country Name City State
n/a

Sponsors (5)

Lead Sponsor Collaborator
McGill University Centre de médecine métabolique de Lanaudière, Centre hospitalier de l'Université de Montréal (CHUM), Centre Hospitalier de l'Université Laval, Institut de Recherches Cliniques de Montreal

References & Publications (7)

Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812. — View Citation

Kruger J, Brennan A, Thokala P, Basarir H, Jacques R, Elliott J, Heller S, Speight J. The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model. Diabet Med. 2013 Oct;30(10):1236-44. doi: 10.1111/dme.12270. Epub 2013 Aug 19. — View Citation

Pereira K, Phillips B, Johnson C, Vorderstrasse A. Internet delivered diabetes self-management education: a review. Diabetes Technol Ther. 2015 Jan;17(1):55-63. doi: 10.1089/dia.2014.0155. — View Citation

Schmitt A, Kulzer B, Ehrmann D, Haak T, Hermanns N. A Self-Report Measure of Diabetes Self-Management for Type 1 and Type 2 Diabetes: The Diabetes Self-Management Questionnaire-Revised (DSMQ-R) - Clinimetric Evidence From Five Studies. Front Clin Diabetes Healthc. 2022 Jan 13;2:823046. doi: 10.3389/fcdhc.2021.823046. eCollection 2021. — View Citation

Stanton-Fay SH, Hamilton K, Chadwick PM, Lorencatto F, Gianfrancesco C, de Zoysa N, Coates E, Cooke D, McBain H, Heller SR, Michie S; DAFNEplus study group. The DAFNEplus programme for sustained type 1 diabetes self management: Intervention development using the Behaviour Change Wheel. Diabet Med. 2021 May;38(5):e14548. doi: 10.1111/dme.14548. Epub 2021 Mar 10. — View Citation

Xie LF, Itzkovitz A, Roy-Fleming A, Da Costa D, Brazeau AS. Understanding Self-Guided Web-Based Educational Interventions for Patients With Chronic Health Conditions: Systematic Review of Intervention Features and Adherence. J Med Internet Res. 2020 Aug 13;22(8):e18355. doi: 10.2196/18355. — View Citation

Xie LF, Roy-Fleming A, Haag S, Costa DD, Brazeau AS. Development of the Support self-guided, web application for adults living with type 1 diabetes in Canada by a multi-disciplinary team using a people-oriented approach based on the Behaviour Change Wheel. Digit Health. 2023 Jan 24;9:20552076231152760. doi: 10.1177/20552076231152760. eCollection 2023 Jan-Dec. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Implementation question Participants will be asked where they heard about the platform. 0 month
Other communication with health care team Question about type (in-person, phone, video call or email) and frequency of communication with health care team 0, 6 and 12 months
Other Engagement with Support platform (T1D patient) - time in minutes on platform Engagement metrics will be extracted using Google analytics - time (minutes) spent on the platform 6, 12 months
Other Engagement with Support platform (T1D patient) - total pages viewed Engagement metrics will be extracted using Google analytics - total pages viewed from the platform 6, 12 months
Other Engagement with Support platform (T1D patient) - downloaded documents Engagement metrics will be extracted using Google analytics - downloaded documents from the platform 6, 12 months
Other Engagement with Support platform (T1D patient) - use of calculators Engagement metrics will be extracted using Google analytics - use of calculators on the platform 6, 12 months
Other Engagement with Support platform (Health Care Provider) - time in minutes on platform Engagement metrics will be extracted using Google analytics - time (minutes) spent on the platform 6, 12 months
Other Engagement with Support platform (Health Care Provider) - content accessed Engagement metrics will be extracted using Google analytics - specific content accessed from the platform 6, 12 months
Other Engagement with Support platform (Health Care Provider) - total pages viewed Engagement metrics will be extracted using Google analytics - total pages viewed from the platform 6, 12 months
Other Engagement with Support platform (Health Care Provider) - downloaded documents Engagement metrics will be extracted using Google analytics - downloaded documents from the platform 6, 12 months
Other Engagement with Support platform (Health Care Provider) - use of calculators Engagement metrics will be extracted using Google analytics - use of calculators on the platform 6, 12 months
Other Satisfaction with Support-t platform - T1D patient Satisfaction will be rated on a scale from 1 to 10. Higher scores indicate greater satisfaction with the platform. 6, 12 months
Other Experience with Support platform (Barriers, facilitators, satisfaction, fidelity) - T1D patient Individual interviews to understand the experience in the context of implementation of the Support-t platform (Barriers, facilitators, satisfaction, fidelity) using qualitative descriptive methodology 12 months
Other Experience with Support platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider Individual interviews to understand the experience in the context of implementation of the Support-t platform (Barriers, facilitators, satisfaction, fidelity) using qualitative descriptive methodology 12 months
Primary Self-efficacy for diabetes management Diabetes Self-Management Questionnaire-Revised (DSMQ-R; 27-items, score on 10) 0, 6 and 12 months
Secondary Well-being WHO-5 well-being index 0, 6 and 12 months
Secondary Continuous Glucose Monitoring (CGM) - % Time in range % Time in range (3.9-10.0mmol/L) over the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap. 0, 6 and 12 months
Secondary Continuous Glucose Monitoring (CGM) - % Time above range % Time above range (3.9-10.0mmol/L) over the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap. 0, 6 and 12 months
Secondary Continuous Glucose Monitoring (CGM) - % Time below range % Time below range (3.9-10.0mmol/L) over the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap. 0, 6 and 12 months
Secondary Continuous Glucose Monitoring (CGM) - Standard deviation Standard deviation of the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap. 0, 6 and 12 months
Secondary Continuous Glucose Monitoring (CGM) - % Coefficient of variation % Coefficient of variation of the past 4 weeks. Participants may share their account access so the research team will be able to export data or may upload a PDF of their data through REDCap. 0, 6 and 12 months
Secondary Hemoglobin A1c self-reported last Hemoglobin A1c (date and value) through online questionnaire 0, 6 and 12 months
Secondary Severe hypoglycemic events Self-reported severe hypoglycemic events in the past 6 months 0, 6 and 12 months
Secondary Diabetic Ketoacidosis (DKA) events Self-reported DKA events in the past 6 months 0, 6 and 12 months
Secondary calls to 911 Self-reported number of calls to 911 in the past 6 months 0, 6 and 12 months
Secondary calls to 811 Self-reported number of calls to 811 in the past 6 months 0, 6 and 12 months
Secondary Cost effectiveness (self-efficacy) Cost effectiveness of access to Support as part of usual care compared with independent access in terms of incremental cost effectiveness ratio (ICER) for self-efficacy 6 and 12 months
Secondary Cost effectiveness (HbA1c) Cost effectiveness of access to Support as part of usual care compared with independent access in terms of incremental cost effectiveness ratio (ICER) for HbA1c 6 and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Active, not recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2